One Year Access to Oncology, Biosimilars, Antibodies, Proteins and Vaccines …DigitalJournal.comThis subscription provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store, including…
One Year Access to Oncology, Biosimilars, Antibodies, Proteins and Vaccines … – PR Newswire (press release)
One Year Access to Oncology, Biosimilars, Antibodies, Proteins and Vaccines …PR Newswire (press release)This subscription provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store, …
When the living, deceased don't agree on organ donation – Science Daily (press release)
|
When the living, deceased don’t agree on organ donation
Science Daily (press release) 26, 2013 — All 50 states and the District of Columbia have adopted the 2006 Revised Uniform Anatomical Gift Act (UAGA) or enacted similar legislation giving individuals the “First Person Authorization” (FPA) to consent to organ donation after death … |
Cancer drug Treanda gets orphan status, but that won't save Teva's shrinking … – FiercePharma
Drug Discovery & Development |
Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …
FiercePharma The orphan tag applies to use of Treanda for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within 6 months of treatment with rituximab or a regimen containing rituximab. Orphan status is granted to therapies intended to … Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva gains additional regulatory exclusivity for TreandaThe Pharma Letter |
OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity … – PR Newswire (press release)
OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity …PR Newswire (press release)OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity Analysis and Forecasts to 2017. Summary Late-stage chronic kidney diseas…
Teva Gets Additional Exclusivity for Treanda – Drug Discovery & Development
Drug Discovery & Development |
Teva Gets Additional Exclusivity for Treanda
Drug Discovery & Development … Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. FDA grants Teva’s Treanda orphan drug statusGlobes Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) |
Gay Chicagoan tells personal tale about blood donation – Windy City Times
|
Gay Chicagoan tells personal tale about blood donation
Windy City Times Mike Quigley ( D-Ill. )—sent a letter to U.S. Department of Health and Human Services ( HHS ) Secretary Kathleen Sebelius, requesting information on the ongoing efforts by HHS to reevaluate blood donation criteria for MSM. “Equality for the LGBT … |
FDA grants Teva's Treanda orphan drug status – Globes
Drug Discovery & Development |
FDA grants Teva’s Treanda orphan drug status
Globes … that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with … Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva Pharma Reports Addl. Regulatory Exclusivity For TREANDA For InjectionNASDAQ |
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory … – 4-traders (press release)
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release)TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months…
Teva Announces Additional Regulatory Exclusivity for TREANDA … – Business Wire (press release)
Drug Discovery & Development |
Teva Announces Additional Regulatory Exclusivity for TREANDA …
Business Wire (press release) TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Important Safety Information. FDA grants Teva’s Treanda orphan drug statusGlobes Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma |